Expression of CD14, IL10, and Tolerogenic Signature in Dendritic Cells Inversely Correlate with Clinical and Immunologic Response to TARP Vaccination in Prostate Cancer Patients

Clinical Cancer Research

Volumn 23, Issue 13, 2017, Pages 3352-3364

  Castiello, Luciano ^a   Sabatino, Marianna ^a   Ren, Jiaqiang ^a   Terabe, Masaki ^c   Khuu, Hanh ^b   Wood, Lauren V ^c   Berzofsky, Jay A ^c   Stroncek, David F ^a  

^a NATIONAL INSTITUTES OF HEALTH   (United States)

^b Pasteur Institute   (Italy)

^c NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD14 ANTIGEN; DENDRITIC CELL VACCINE; INTERLEUKIN 10; MONOCYTE CHEMOTACTIC PROTEIN 1; TRANSCRIPTOME; CANCER VACCINE; CCL2 PROTEIN, HUMAN; LIPOPOLYSACCHARIDE RECEPTOR; NUCLEAR PROTEIN; TARP;

ANTIGEN SPECIFICITY; ARTICLE; CANCER IMMUNIZATION; CELL VIABILITY; CLINICAL ARTICLE; CLINICAL EFFECTIVENESS; CONTROLLED STUDY; CYTOKINE RELEASE; DISEASE ASSOCIATION; DRUG EFFICACY; DRUG POTENCY; GENE EXPRESSION PROFILING; GENETIC ASSOCIATION; HUMAN; HUMAN CELL; IMMUNE RESPONSE; MALE; PRIORITY JOURNAL; PROSTATE CARCINOMA; PROTEIN EXPRESSION; RANDOMIZED CONTROLLED TRIAL; ADOLESCENT; ADULT; AGED; BIOLOGICAL THERAPY; CLINICAL TRIAL; DENDRITIC CELL; GENE EXPRESSION REGULATION; GENETICS; IMMUNOLOGY; MIDDLE AGED; PATHOLOGY; PHASE 1 CLINICAL TRIAL; PROCEDURES; PROSTATE TUMOR; TREATMENT OUTCOME;

ADOLESCENT; ADULT; AGED; CANCER VACCINES; CELL- AND TISSUE-BASED THERAPY; CHEMOKINE CCL2; DENDRITIC CELLS; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; INTERLEUKIN-10; LIPOPOLYSACCHARIDE RECEPTORS; MALE; MIDDLE AGED; NUCLEAR PROTEINS; PROSTATIC NEOPLASMS; TREATMENT OUTCOME;

EID: 85021734814     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-16-2199     Document Type: Article

References (55)

1. Ueno H, Schmitt N, Klechevsky E, Pedroza-Gonzalez A, Matsui T, Zurawski G, et al. Harnessing human dendritic cell subsets for medicine. Immunol Rev 2010;234:199–212.
2. Sallusto F, Lanzavecchia A. Efficient presentation of soluble antigen by cultured human dendritic cells is maintained by granulocyte/macrophage colony-stimulating factor plus interleukin 4 and downregulated by tumor necrosis factor alpha. J Exp Med 1994;179:1109–18.
3. Castiello L, Sabatino M, Jin P, Clayberger C, Marincola FM, Krensky AM, et al. Monocyte-derived DC maturation strategies and related pathways: a transcriptional view. Cancer Immunol Immunother 2011;60:457–66.
4. Anguille S, Smits EL, Lion E, van Tendeloo VF, Berneman ZN. Clinical use of dendritic cells for cancer therapy. Lancet Oncol 2014;15:e257–67.
5. Stroncek DF, Jin P, Ren J, Feng J, Castiello L, Civini S, et al. Quality assessment of cellular therapies: the emerging role of molecular assays. Korean J Hematol 2010;45:14–22.
6. Vatsan RS, Bross PF, Liu K, Theoret M, De Claro AR, Lu J, et al. Regulation of immunotherapeutic products for cancer and FDA's role in product development and clinical evaluation. J Immunother Cancer 2013;1:5.
7. Carreno BM, Becker-Hapak M, Huang A, Chan M, Alyasiry A, Lie W-R, et al. IL-12p70–producing patient DC vaccine elicits Tc1-polarized immunity. J Clin Invest 2013;123:3383–94.
8. Kalinski P, Urban J, Narang R, Berk E, Wieckowski E, Muthuswamy R. Dendriticcell-basedtherapeuticcancervaccines:whatwehaveandwhatwe need. Future Oncol 2009;5:379–90.
9. Vieira PL, de Jong EC, Wierenga EA, Kapsenberg ML, Kalin´ski P. Development of TH1-inducing capacity in myeloid dendritic cells requires environmental instruction. J Immunol 2000;164:4507–12.
10. Torres-Aguilar H, Aguilar-Ruiz SR, Gonzalez-Perez G, Munguía R, Bajaña S, Meraz-Ríos MA, et al. Tolerogenic dendritic cells generated with different immunosuppressive cytokines induce antigen-specific anergy and regulatory properties in memory CD4þ T cells. J Immunol 2010;184:1765–75.
11. Chitta S, Santambrogio L, Stern LJ. GMCSF in the absence of other cytokines sustains human dendritic cell precursors with T cell regulatory activity and capacity to differentiate into functional dendritic cells. Immunol Lett 2008;116:41–54.
12. Castiello L, Sabatino M, Zhao Y, Tumaini B, Ren J, Ping J, et al. Quality controls in cellular immunotherapies: rapid assessment of clinical grade dendritic cells by gene expression profiling. Mol Ther 2013;21:476–84.
13. Wood LV, Fojo A, Roberson BD, Hughes MSB, Dahut W, Gulley JL, et al. TARP vaccination is associated with slowing in PSA velocity and decreasing tumor growth rates in patients with Stage D0 prostate cancer. Oncoim-munology 2016;5:e1197459.
14. Vickers AJ, Brewster SF. PSA velocity and doubling time in diagnosis and prognosis of prostate cancer. Br J Med Surg Urol 2012;5:162–8.
15. Epel M, Carmi I, Soueid-Baumgarten S, Oh SK, Bera T, Pastan I, et al. Targeting TARP, a novel breast and prostate tumor-associated antigen, with T cell receptor-like human recombinant antibodies. Eur J Immunol 2008;38:1706–20.
16. Robin X, Turck N, Hainard A, Tiberti N, Lisacek F, Sanchez J-C, et al. pROC: an open-source package for R and Sþ to analyze and compare ROC curves. BMC Bioinformatics 2011;12:77.
17. Hanley JA, McNeil BJ. The meaning and use of the area under a receiver operating characteristic (ROC) curve. Radiology 1982;143:29–36.
18. Soric B. Statistical "Discoveries" and Effect-Size Estimation. J Am Stat Assoc 1989;84:608–10.
19. Langfelder P, Horvath S. WGCNA: an R package for weighted correlation network analysis. BMC Bioinformatics 2008;9:559.
20. Huang DW, Sherman BT, Lempicki RA. Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nat Protoc 2009;4:44–57.
21. Eisen MB, Spellman PT, Brown PO, Botstein D. Cluster analysis and display of genome-wide expression patterns. Proc Natl Acad Sci U S A 1998;95:14863–8.
22. Saldanha AJ. Java Treeview–extensible visualization of microarray data. Bioinformatics 2004;20:3246–8.
23. Edgar R, Domrachev M, Lash AE. Gene Expression Omnibus: NCBI gene expression and hybridization array data repository. Nucleic Acids Res 2002;30:207–10.
24. Gregori S, Tomasoni D, Pacciani V, Scirpoli M, Battaglia M, Magnani CF, et al. Differentiation of type 1 T regulatory cells (Tr1) by tolerogenic DC-10 requires the IL-10-dependent ILT4/HLA-G pathway. Blood 2010; 116:935–44.
25. Rutella S, Bonanno G, Procoli A, Mariotti A, de Ritis DG, Curti A, et al. Hepatocyte growth factor favors monocyte differentiation into regulatory interleukin (IL)-10þþIL-12low/neg accessory cells with dendritic-cell features. Blood 2006;108:218–27.
26. Krispin A, Bledi Y, Atallah M, Trahtemberg U, Verbovetski I, Nahari E, et al. Apoptotic cell thrombospondin-1 and heparin-binding domain lead to dendritic-cell phagocytic and tolerizing states. Blood 2006;108:3580–9.
27. Pulendran B, Tang H, Manicassamy S. Programming dendritic cells to induce T(H)2 and tolerogenic responses. Nat Immunol 2010;11:647–55.
28. Whiteside TL. Immune modulation of T-cell and NK (natural killer) cell activities by TEXs (tumour-derived exosomes). Biochem Soc Trans 2013;41:245–51.
29. Whiteside TL. Immune suppression in cancer: effects on immune cells, mechanisms and future therapeutic intervention. Semin Cancer Biol 2006;16:3–15.
30. Vasaturo A, Di Blasio S, Peeters DG, de Koning CCH, de Vries JM, Figdor CG, et al. Clinical implications of co-inhibitory molecule expression in the tumor microenvironment for DC vaccination: a game of stop and go. Front Immunol 2013;4:417.
31. Hargadon KM. Tumor-altered dendritic cell function: implications for anti-tumor immunity. Front Immunol 2013;4:192.
32. Decker P, Kotter € I, Klein R, Berner B, Rammensee H-G. Monocyte-derived dendritic cells over-express CD86 in patients with systemic lupus erythe-matosus. Rheumatology 2006;45:1087–95.
33. van den Heuvel MM, Vanhee DD, Postmus PE, Hoefsmit EC, Beelen RH. Functional and phenotypic differences of monocyte-derived dendritic cells from allergic and nonallergic patients. J Allergy Clin Immunol 1998;101: 90–5.
34. Cuellar A, Santander SP, Thomas MDC, Guzman F, Gomez A, Lopez MC, et al. Monocyte-derived dendritic cells from chagasic patients vs. healthy donors secrete differential levels of IL-10 and IL-12 when stimulated with a protein fragment of Trypanosoma cruzi heat-shock protein-70. Immunol Cell Biol 2008;86:255–60.
35. Kvistborg P, Bechmann CM, Pedersen AW, Toh HC, Claesson MH, Zocca MB. Comparison of monocyte-derived dendritic cells from colorectal cancer patients, non-small-cell-lung-cancer patients and healthy donors. Vaccine 2009;28:542–7.
36. Butterfield LH. Dendritic cells in cancer immunotherapy clinical trials: are we making progress? Front Immunol 2013;4:454.
37. Wurfel MM, Park WY, Radella F, Ruzinski J, Sandstrom A, Strout J, et al. Identification of high and low responders to lipopolysaccharide in normal subjects: an unbiased approach to identify modulators of innate immunity. J Immunol 2005;175:2570–8.
38. Peng JC, Abu Bakar S, Richardson MM, Jonsson JJ, Frazer IH, Nielsen LK, et al. IL10 and IL12B polymorphisms each influence IL-12p70 secretion by dendritic cells in response to LPS. Immunol Cell Biol 2006;84:227–32.
39. Beckebaum S, Zhang X, Chen X, Yu Z, Frilling A, Dworacki G, et al. Increased levels of interleukin-10 in serum from patients with hepatocellular carcinoma correlate with profound numerical deficiencies and immature phenotype of circulating dendritic cell subsets. Clin Cancer Res 2004;10:7260–9.
40. Bellone G, Carbone A, Smirne C, Scirelli T, Buffolino A, Novarino A, et al. Cooperative induction of a tolerogenic dendritic cell phenotype by cytokines secreted by pancreatic carcinoma cells. J Immunol 2006; 177:3448–60.
41. Fucíkova J, Rozkova D, Ulcova H, Budinsky V, Sochorova K, Pokorna K, et al. Poly I: C-activated dendritic cells that were generated in CellGro for use in cancer immunotherapy trials. J Transl Med 2011; 9:223.
42. Lurquin C, Lethe B, De Plaen E, Corbiere V, Theate I, van Baren N, et al. Contrasting frequencies of antitumor and anti-vaccine T cells in metastases of a melanoma patient vaccinated with a MAGE tumor antigen. J Exp Med 2005;201:249–57.
43. Lonchay C, van der Bruggen P, Connerotte T, Hanagiri T, Coulie P, Colau D, et al. Correlation between tumor regression and T cell responses in melanoma patients vaccinated with a MAGE antigen. Proc Natl Acad Sci U S A 2004;14631–8.
44. Van Elssen CHMJ, Oth T, Germeraad WTV, Bos GMJ, Vanderlocht J. Natural killer cells: the secret weapon in dendritic cell vaccination strategies. Clin Cancer Res 2014;20;1095–103.
45. Palucka K, Banchereau J. Cancer immunotherapy via dendritic cells. Nat Rev Cancer 2012;12:265–77.
46. Kamath AT, Sheasby CE, Tough DF. Dendritic cells and NK cells stimulate bystander T cell activation in response to TLR agonists through secretion of IFN-alpha beta and IFN-gamma. J Immunol 2005;174:767–76.
47. GabrilovichDI,NagarajS.Myeloid-derivedsuppressorcellsasregulatorsof the immune system. Nat Rev Immunol 2009;9:162–74.
48. Chang C-H, Qiu J, O'Sullivan D, Buck MD, Noguchi T, Curtis JD, et al. Metabolic competition in the tumor microenvironment is a driver of cancer progression. Cell 2015;162:1229–41.
49. Zarour HM. Reversing T-cell dysfunction and exhaustion in cancer. Clin Cancer Res 2016;22:1856–64.
50. Steinman RM, Banchereau J. Taking dendritic cells into medicine. Nature 2007;449:419–26.
51. Bray SM, Vujanovic L, Butterfield LH. Dendritic cell-based vaccines positively impact natural killer and regulatory T cells in hepatocellular carcinoma patients. Clin Dev Immunol 2011;2011: 249281.
52. Jansen BJH, Sama IE, Eleveld-Trancikova D, van Hout-Kuijer MA, Jansen JH, Huynen MA, et al. MicroRNA genes preferentially expressed in dendritic cells contain sites for conserved transcription factor binding motifs in their promoters. BMC Genomics 2011;12:330.
53. Aldinucci A, Rizzetto L, Pieri L, Nosi D, Romagnoli P, Biagioli T, et al. Inhibition of immune synapse by altered dendritic cell actin distribution: a new pathway of mesenchymal stem cell immune regulation. J Immunol 2010;185:5102–10.
54. Zhang X-L, Peng J, Sun J-Z, Liu J-J, Guo C-S, Wang Z-G, et al. De novo induction of platelet-specific CD4(þ)CD25(þ) regulatory T cells from CD4(þ)CD25(-) cells in patients with idiopathic thrombocytopenic pur-pura. Blood 2009;113:2568–77.
55. Jiang A, Bloom O, Ono S, Cui W, Unternaehrer J, Jiang S, et al. Disruption of E-cadherin-mediated adhesion induces a functionally distinct pathway of dendritic cell maturation. Immunity 2007;27:610–24.